Form 8-K Salarius Pharmaceuticals For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- AMD shares fall amid AI chip sector selloff
- Alphabet shares drop ahead of earnings next week
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Salarius Pharmaceuticals faces Nasdaq delisting over stock price
January 2, 2026 5:16 PM ESTSalarius Pharmaceuticals, Inc. (NASDAQ: SLRX) received notice from Nasdaq on December 31, 2025, stating the company fails to meet minimum bid price requirements for continued listing on The Nasdaq Capital Market.
The company's stock closed below $1.00 per share for 30 consecutive business days, violating Nasdaq... More



